Human trials of indigenously developed Covid vaccines move to Phase 2: ICMR

Bhargava said once a safe and effective vaccine is developed, the focus should be on prioritisation and its fair distribution, roll-out and cold chain logistics

covid, coronavirus, vaccine, drug, pharma
There are about 141 candidates that are being studied world over and 26 are in different phases of clinical trials, he said.
Press Trust of India New Delhi
2 min read Last Updated : Aug 04 2020 | 10:34 PM IST
The Phase 1 human clinical trials of two Covid-19 vaccine candidates developed indigenously by Bharat Biotech in collaboration with ICMR and Zydus Cadila Ltd have been completed and the trials have moved to Phase 2, ICMR Director General Balram Bhargava said on Tuesday.

Addressing a press briefing, he said once a safe and effective vaccine is developed, the focus should be on prioritisation and its fair distribution, roll-out and cold chain logistics, stockpiling and training of people who would be administering the vaccine.

There are about 141 candidates that are being studied world over and 26 are in different phases of clinical trials, he said.

"At the present moment, there are three vaccines that are in different phases of clinical testing in India. The first one is the inactivated virus vaccine developed by Bharat Biotech which has completed its Phase 1 study in 11 sites and has started its Phase 2 study. Phase 1 and 2 are safety and very early efficacy studies.
"Similarly Zydus Cadila's DNA vaccine has also completed Phase 1 studies in 11 sites and started its Phase 2 trials which is also progressing. Recombinant Oxford vaccine to be manufactured by Serum Institute of India, Pune was given approval yesterday for Phase 2 and 3 clinical trials which would start within a week at 17 sites," Bhargava said at the briefing.

Underlining the urgency for the need of a vaccine, the ICMR official said though the pandemic is progressing rapidly, developing a vaccine takes time "not only from the science aspect, but also from the social, cultural and regulatory aspects".

He, however, emphasised that till a safe and effective vaccine becomes available, sustained behavioural change, physical distancing, wearing masks and proper hand hygiene, is probably the best vaccine available at the moment, and even these measures have to be continued absolutely.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineICMR

Next Story